CureVac (NASDAQ:CVAC – Get Rating) shares reached a new 52-week low during trading on Monday . The company traded as low as $9.35 and last traded at $9.47, with a volume of 107 shares. The stock had previously closed at $9.57.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reissued a “buy” rating and issued a $37.00 target price on shares of CureVac in a research report on Thursday, June 9th.
CureVac Stock Performance
The business’s fifty day moving average price is $11.86 and its 200 day moving average price is $15.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.45 and a quick ratio of 3.39.
Institutional Inflows and Outflows
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.